Company Description
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases.
The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.
In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN).
The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.
Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 10, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Aoife Brennan |
Contact Details
Address: 20 William Street, Suite 145 Wellesley Hills, Massachusetts 02481 United States | |
| Phone | 866 857 2596 |
| Website | climbbio.com |
Stock Details
| Ticker Symbol | CLYM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001768446 |
| ISIN Number | US28658R1068 |
| Employer ID | 83-2273741 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Interim Principal Financial Officer, Chief Executive Officer, President and Director |
| Chandra Adams J.D. | Vice President and General Counsel |
| Dr. Nishi Rampal M.D. | Senior Vice President of Clinical Development |
| Janaki M. Subramanyam M.Sc. | Vice President and Head of Regulatory Affairs |
| Kate Hecht M.B.A. | Senior Vice President of Program Management |
| Dr. Perrin Wilson B.S., Ph.D. | Chief Business Officer |
| Dr. Edgar D. Charles M.D., M.Sc. | Chief Medical Officer |
| Cindy J. Driscoll M.B.A. | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Jun 18, 2025 | 8-K | Current Report |
| Jun 5, 2025 | 8-K | Current Report |
| May 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 23, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |